LANGUAGE
KOREAN
ENGLISH
LOCATION
COMPANY
R&D
R&D Institute
GMP Center
Clinical Development Status
Publications
PRODUCTS
1st Generation
Overview
CARTISTEM
®
PNEUMOSTEM
®
2nd Generation
Overview
SMUP-IA-01
SMUP-IV-01
R&D Inquiries
BUSINESS
CDMO
Quality System
CDMO Service
Quality Control
Global CDMO
CDMO Inquiries
CELLTREE Cord Blood Bank
MOVITA Nutritional Supplements
IR
Stock Information
Disclosure
Financial Information
IR Inquiries
PR
MEDIPOST on Media
Corporate Brochure
CONTACT US
Customer Center
R&D Inquiries
CDMO Inquiries
IR Inquiries
Institute
GMP Center
Development Status
Publications
Publications
Implantation of allogenic umbilical cord blood-derived mesenchymal stem cells improves knee osteoarthritis outcomes: Two-year f
CARTISTEM
Date
2020-01-14 12:30
Views
83
Issue information
:
Regen Ther. 2020 Jan 14;14:32-39. doi: 10.1016/j.reth.2019.10.003.
Co-author
:
Jun-Seob Song, Ki-Taek Hong, Na-Min Kim, Jae-Yub Jung, Han-Soo Park, Sang Heon Lee, Yoon Joo Cho, Seok Jung Kim
Link
:
https://pubmed.ncbi.nlm.nih.gov/31988992/
Implantation of CARTISTEM showed effective clinical outcome for treating knee osteoarthritis based on a follow-up lasting a minimum of 2 years.
Print
«
Up-Regulation of Superoxide Dismutase 2 in 3D Spheroid Formation Promotes Therapeutic Potency of Human Umbilical Cord Blood-Der
Soluble PTX3 of Human Umbilical Cord Blood-Derived Mesenchymal Stem Cells Attenuate Hyperoxic Lung Injury by Activating Macroph
»
List
Institute
GMP Center
Development Status
Publications
Menu